Keros Therapeutics (KROS) Non-Current Assets (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Non-Current Assets came in at $22.6 million in Q4 2025, down 16.32% YoY from $27.0 million in Q4 2024, and down 3.79% on a QoQ basis from $23.5 million in Q3 2025.
Keros Therapeutics (KROS) Non-Current Assets (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Non-Current Assets data on file, last reported at $22.6 million in Q4 2025.
- Quarterly Non-Current Assets fell 16.32% year-over-year to $22.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $95.5 million (down 3.78% YoY) and the FY2025 annual result came in at $22.6 million, down 16.32% from the prior year.
- Non-Current Assets retreated to $22.6 million in Q4 2025, from $23.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $27.2 million in Q3 2024 to a low of $1.7 million in Q1 2021.
- A 5-year average of $16.5 million and a median of $22.1 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 466.39% — and 2025, when it decreased 16.32%.
- Tracing KROS's Non-Current Assets over 5 years: stood at $3.8 million in 2021, then soared by 451.4% to $21.0 million in 2022, then grew by 8.18% to $22.7 million in 2023, then rose by 18.74% to $27.0 million in 2024, then declined by 16.32% to $22.6 million in 2025.
- The last three Non-Current Assets figures came in at $22.6 million (Q4 2025), $23.5 million (Q3 2025), and $24.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | 20.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.72 Mn |
| Dec 31, 2025 | 22.59 Mn |
| Sep 30, 2025 | 23.48 Mn |
| Jun 30, 2025 | 24.36 Mn |
| Mar 31, 2025 | 25.05 Mn |
| Dec 31, 2024 | 26.99 Mn |
| Sep 30, 2024 | 27.23 Mn |
| Jun 30, 2024 | 22.31 Mn |
| Mar 31, 2024 | 22.69 Mn |
| Dec 31, 2023 | 22.73 Mn |
| Sep 30, 2023 | 21.81 Mn |
| Jun 30, 2023 | 22.00 Mn |
| Mar 31, 2023 | 22.21 Mn |
| Dec 31, 2022 | 21.01 Mn |
| Sep 30, 2022 | 6.68 Mn |
| Jun 30, 2022 | 4.30 Mn |
| Mar 31, 2022 | 3.92 Mn |
| Dec 31, 2021 | 3.81 Mn |
| Sep 30, 2021 | 3.89 Mn |
| Jun 30, 2021 | 2.04 Mn |